Navigation Links
Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World
Date:5/6/2010

/a>; Swiss Exchange: CRX) is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. In 2009 alone, Crucell distributed more than 115 million vaccine doses in more than 100 countries around the world, with the fast majority of doses (97%) going to developing countries. Crucell is one of the major suppliers of vaccines to UNICEF and the developing world. Crucell was the first manufacturer to launch a fully-liquid pentavalent vaccine called Quinvaxem(R). Quinvaxem(R) protects against five important childhood diseases and over 130 million doses have been sold since its launch in 2006 in more than 50 GAVI countries. Through Quinvaxem(R) and its innovation, Crucell has become a major partner in protecting children in developing countries. Crucell's core portfolio also includes a vaccine against hepatitis B and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as an oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6(R) production technology. The Company licenses its PER.C6(R) technology and other technologies to the biopharmaceutical industry. Important partners and licensees include Johnson & Johnson, DSM Biologics, sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Argentina, China, Italy, Korea, Spain, Sweden, Switzerland, UK and the USA. The Company employs over 1200 people. For more information, p
'/>"/>
SOURCE Crucell N.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
2. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
3. DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
4. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... YORK , July 29, 2014  Pomerantz LLP ... Laboratories, Inc. ("Impax" or the "Company") (NASDAQ: IPXL).  Such ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On July 29, 2014, Impax Laboratories, ...
(Date:7/29/2014)... According to the new research ... (Image Analysis Software), Delivery Modes (Web Based/Cloud Based) & ... to 2018", published by MarketsandMarkets, analyzes and studies the ... North America , Europe ... Rest of the World (RoW). Browse 78 ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, ... with FORMA Therapeutics, Inc., to provide access to ... fragment-based lead discovery platform for novel small molecule ... about the opportunity to work with FORMA Therapeutics ... epigenetics and protein homeostasis. FORMA Therapeutics, decision to ...
(Date:7/29/2014)... , July 29, 2014  Cannabis Science, ... cannabis formulation-based drug development and related consulting, applauds ... for taking a strong position in opposition to ... July 27, 2014 publication.  The New York Times ... articles this week exploring the issue called "High ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3
... Call Today at 4:30 p.m. Eastern Time - SAN FRANCISCO, March ... today reported on its corporate progress and financial results ... a very productive 2008 and are looking forward to an equally ... are on track to be in Phase 3 testing in all ...
... announces that its lead compound for inhibition of tau ... has been recognized as the most potent inhibitor of ... to date. Mutations of this gene are believed ... frequent cause of Parkinson,s Disease.TauTaTis, lead compound is a ...
... Traceability Down to the Unit Level to Secure Products and ... ... Southborough, MA (PRWEB) March 16, 2009 -- PHARMORX Security™, a ... provider, today announced the availability of its new comprehensive technology ...
Cached Biology Technology:Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 2Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 3Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 4Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 5Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 6Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 7Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 8TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 3
(Date:7/29/2014)... Helping people recover from the debilitating effects of ... requires deep knowledge of neurophysiology as well as ... options and outcomes has been the primary focus ... biomedical engineering, since he joined the NJIT faculty ... whose significance is underscored by substantial funding from ...
(Date:7/29/2014)... Dentistry (UM SOD) and Medicine (UM SOM) jointly ... $10.7 million grant award from the National Institute ... National Institutes of Health to study the causes, ... grant, which renews a previous $12 million five-year ... the research by studying chlamydial and gonorrheal diseases ...
(Date:7/29/2014)... brings together two of the major disciplines behind Jurassic ... fossils through stunning photographs and unique illustrations. , Fossil ... details the incredible preservation and diversity of fossilised insects ... these remarkable fossils can tell us about the ancient ... planet. Like the mosquito in Jurassic Park, many of ...
Breaking Biology News(10 mins):Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4Unique images bring fossil insects back to life 2
... ecosystem below an Antarctic glacier and learned that it survived ... growth. Described in the April 17 issue of ... a pool of brine trapped below Taylor Glacier and next ... Priscu , co-author of the Science article. Priscu ...
... over, Y chromosome it,s time X got some ... chromosome associated with being female, University of California, Berkeley, ... history of the X chromosome is every bit as ... important clues to the origins and benefits of sexual ...
... Sven Enerbck, Professor at the Institute of Biomedicine at the ... scientists who published their results in The New England ... Enerbck and others show that adults use brown fat to ... new possibilities in treating overweight and obesity. It has ...
Cached Biology News:Ancient ecosystem thrives millions of years below Antarctic glacier 2The story of X -- evolution of a sex chromosome 2The story of X -- evolution of a sex chromosome 3The story of X -- evolution of a sex chromosome 4
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
MAGP-2 (C-19)...
... ZMD.473. Immunogen: Synthetic peptide derived ... mouse junctophilin-2. Specificity: Specific for ... (positive controls: mouse skeletal muscle homogenates ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: Store ...
TGF-beta 2 MAb (Clone 8607)...
Biology Products: